Wellysis Corp. announced that it has issued redeemable convertible preferred stocks for gross proceeds of KRW 5,000,000,000 in a round of funding on May 30, 2022. The transaction included participation from Access Bio, Inc.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6,670 KRW | -1.19% | -4.85% | -25.64% |
2023 | Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc. | CI |
2023 | Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022. | CI |
1st Jan change | Capi. | |
---|---|---|
-25.64% | 165M | |
-5.12% | 8.05B | |
+8.59% | 5.84B | |
+31.71% | 5.66B | |
-12.56% | 3.99B | |
+12.16% | 2.7B | |
-59.74% | 2.7B | |
-6.88% | 2.39B | |
+16.51% | 2.02B | |
-7.86% | 1.8B |
- Stock Market
- Equities
- A950130 Stock
- News Access Bio, Inc.
- Wellysis announced that it has received KRW 5 billion in funding from Access Bio, Inc.